As part of the agreement, Galderma will carry on the ongoing NVC-422 clinical development program for impetigo and NovaBay will receive double-digit royalties on net sales of products.
NovaBay has withheld certain rights to Asian markets, onychomycosis, post surgical use and use in wound care and orphan drug indications.
Excluding Japan, NovaBay has also retained all rights in Asian markets to promote the products developed in hospitals and other healthcare institutions in North America.
Galderma and NovaBay enrolled first patient for impetigo treatment phase 2b global trial and are expecting the results from the trial in the first half of 2013.